Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (14901)	12/23/2004 10:42:17 AM
From: rkrw	Respond to of 52153

adlr call was on the fda decision. But I don't mind taking credit for predicting this failure even though I had no idea there was a european trial :-) PDUFA isn't until the Spring. So still a chance I could be wrong. Todays news won't help their cause though. I saw them present at Rodman Renshaw, breakout room the ceo performance was wretched. Probably the worst I've ever seen. NDA filing was based on two pivotal trials, mixed outcome, overall benefit seems marginal. adlr says put them together and they look good. I think their best case is approvable and do another trial.